ArticleThe primary care companion for CNS disorders2015
A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder.
Article in The primary care companion for CNS disorders, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01712321 (Vilazodone in the Treatment of Social Anxiety Disorder), which is not on this map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Antidepressants for social anxiety disorder: A systematic review and meta-analysis.Neuropsychopharmacology reports · 2022Pooled it
- Pharmacotherapy for social anxiety disorder (SAnD).The Cochrane database of systematic reviews · 2017Pooled it
- Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-ExperimentalCannabis and cannabinoid research · 2024Trial
- Melatonin as a Potential Approach to Anxiety Treatment.International journal of molecular sciences · 2022Review
- Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.Focus (American Psychiatric Publishing) · 2021Article
- Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.Frontiers in psychiatry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine the efficacy, safety, and tolerability of vilazodone for subjects (aged 18-75 years) with generalized social anxiety disorder.
methodForty-four subjects with generalized social anxiety disorder (DSM-IV-TR criteria) were randomized to vilazodone or placebo in a 12-week double-blind, flexible-dose trial. Change from baseline to endpoint on the Liebowitz Social Anxiety Scale (LSAS) was the primary outcome measure. Secondary outcome measures included response and remission rates and changes in depression and anxiety. Data were collected between November 2012 and April 2014. The study was conducted at a private clinical trials facility in New York, New York.
resultsThe mean baseline LSAS score was 91.9 (SD = 17.5) and the mean Clinical Global Impressions-Severity scale score was 5.3 (SD = 0.56), indicating marked to severe illness. There were no significant baseline differences in severity of social anxiety between the treatment groups. At the end of treatment, in the intent-to-treat sample (n = 39), the vilazodone group had improved significantly more than the placebo group by 14.3 points on the LSAS (t = 1.80, P = .04, one-tail test) (Cohen d = 0.58).
conclusionsThe findings suggest that vilazodone may be a promising treatment for social anxiety disorder. Further study is needed given the limited sample size.
trial registrationClinicalTrials.gov identifier: NCT01712321.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.